Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience

por Begna, K, Abdelatif, A, Schwager, S, Hanson, C, Pardanani, A, Tefferi, A
Publicado 2016

IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes

por Pardanani, A, Finke, C, Lasho, T L, Al-Kali, A, Begna, K H, Hanson, C A, Tefferi, A
Publicado 2012

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

por Caramazza, D, Begna, K H, Gangat, N, Vaidya, R, Siragusa, S, Van Dyke, D L, Hanson, C, Pardanani, A, Tefferi, A
Publicado 2011

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis

por Tefferi, A, Al-Kali, A, Begna, K H, Patnaik, M M, Lasho, T L, Rizo, A, Wan, Y, Hanson, C A
Publicado 2016

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

por Barraco, D, Elala, Y C, Lasho, T L, Begna, K H, Gangat, N, Finke, C, Hanson, C A, Ketterling, R P, Pardanani, A, Tefferi, A
Publicado 2016

Survival trends in primary myelodysplastic syndromes: a comparative analysis of 1000 patients by year of diagnosis and treatment

por Gangat, N, Patnaik, M M, Begna, K, Al-Kali, A, Litzow, M R, Ketterling, R P, Hanson, C A, Pardanani, A D, Tefferi, A
Publicado 2016

Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations

por Barraco, D, Elala, Y C, Lasho, T L, Begna, K H, Gangat, N, Finke, C, Hanson, C A, Ketterling, R P, Pardanani, A, Tefferi, A
Publicado 2016

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

por Pardanani, A, Laborde, R R, Lasho, T L, Finke, C, Begna, K, Al-Kali, A, Hogan, W J, Litzow, M R, Leontovich, A, Kowalski, M, Tefferi, A
Publicado 2013

1622P The impact of COVID-19 on cancer treatment delivery in Sub-Saharan Africa

por Merrell, K., Ochieng, P., Osei - Bonsu, E.B., Seife, E., Kemper, K., Begna, K., Bussman, S., Leavitt, T., Acheamfour, O., Vanderpuye, V., Manirakiza, A., DeWees, T., Addison, E.
Publicado 2021

Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis

por Pardanani, A, Abdelrahman, R A, Finke, C, Lasho, T T, Begna, K H, Al-Kali, A, Hogan, W J, Litzow, M R, Hanson, C A, Ketterling, R P, Tefferi, A
Publicado 2015

Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients

por Saeed, L, Patnaik, M M, Begna, K H, Al-Kali, A, Litzow, M R, Hanson, C A, Ketterling, R P, Porrata, L F, Pardanani, A, Gangat, N, Tefferi, A
Publicado 2017

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

por Begna, K. H., Kittur, J., Gangat, N., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Pardanani, A., Hanson, C. A., Ketterling, R. P., Tefferi, A.
Publicado 2022

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

por Begna, K. H., Xu, X., Gangat, N., Alkhateeb, H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Wolanskyj-Spinner, A. P., Mangaonkar, A., He, R., Pardanani, A., Shah, M., Ketterling, R. P., Tefferi, A.
Publicado 2022

COVID-19 in Sub-Saharan Africa: A Multi-Institutional Survey of the Impact of the Global Pandemic on Cancer Care Resources

por Merrell, K.W., DeWees, T.A., Osei-Bonsu, E.B., Acheamfour, O., Manirakiza, A.V.C., Avery, S.M., Mallum, A.A.I., Adjei, E., Garda, A.E., Steiner, T., Leavitt, T., Lucido, J., Ndlovu, N., Ngwa, W., Ntekim, A., Vanderpuye, V., Addison, E.C.D.K., Woldetsadik, E.S., Ochieng, P., Begna, K.H.
Publicado 2021